{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:57:30Z","timestamp":1761562650310,"version":"3.40.3"},"publisher-location":"Singapore","reference-count":91,"publisher":"Springer Singapore","isbn-type":[{"type":"print","value":"9789811527234"},{"type":"electronic","value":"9789811527241"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-981-15-2724-1_10","type":"book-chapter","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T11:05:18Z","timestamp":1592219118000},"page":"261-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Public Participation in Access to Medicines"],"prefix":"10.1007","author":[{"given":"Sofia","family":"Cris\u00f3stomo","sequence":"first","affiliation":[]},{"given":"Filipa Alves","family":"da Costa","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"10_CR1","unstructured":"Declaration of Alma-Ata. In: International Conference on Primary Health Care, 6\u201312 September [Internet]. Alma-ata, USSR: World Health Organization; 1978. Available from: www.who.int\/publications\/almaata_declaration_en.pdf?ua=1"},{"key":"10_CR2","unstructured":"Council of Europe. Recommendation No. R (2000) 5 of the Committee of Ministers to member states on the development of structures for citizen and patient participation in the decision-making process affecting health care [Internet]. Strasbourg, France: Council of Europe; 2000. Available from: http:\/\/wcd.coe.int\/ViewDoc.jsp?id=340437&Site=CM"},{"key":"10_CR3","doi-asserted-by":"crossref","unstructured":"Florin D. Public involvement in health care. BMJ [Internet]. 2004 Jan 17;328(7432):159\u201361. Available from: http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.328.7432.159","DOI":"10.1136\/bmj.328.7432.159"},{"issue":"3","key":"10_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.healthpol.2009.01.005","volume":"91","author":"C Mitton","year":"2009","unstructured":"Mitton C, Smith N, Peacock S, Evoy B, Abelson J. Public participation in health care priority setting: A scoping review. Health Policy. 2009;91(3):219\u201328.","journal-title":"Health Policy."},{"key":"10_CR5","unstructured":"European Patients\u2019 Forum. Patient Empowerment Campaign [Internet]. 2015 [cited 2016 Oct 28]. Available from: www.eu-patient.eu\/campaign\/PatientsprescribE"},{"key":"10_CR6","unstructured":"Kickbusch I, Gleicher D. Governance for Health in the 21st Century [Internet]. Copenhagen: WHO Regional Office for Europe; 2012. Available from: www.euro.who.int\/__data\/assets\/pdf_file\/0019\/171334\/RC62BD01-Governance-for-Health-Web.pdf"},{"key":"10_CR7","unstructured":"World Health Organization. Framework on integrated people-centred health services. Report by the Secretariat. [Internet]. 2016. Available from: http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA69\/A69_39-en.pdf?ua=1&ua=1"},{"key":"10_CR8","doi-asserted-by":"crossref","unstructured":"Ives J, Damery S, Redwod S. PPI, paradoxes and Plato: who\u2019s sailing the ship?: Table 1. J Med Ethics [Internet]. 2013 Mar;39(3):181\u20135. Available from: http:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/medethics-2011-100150","DOI":"10.1136\/medethics-2011-100150"},{"key":"10_CR9","unstructured":"International Alliance of Patients\u2019 Organizations. Policy statement. Patient Involvement [Internet]. London; 2005. Available from: http:\/\/iapo.org.uk\/sites\/default\/files\/files\/IAPOPolicyStatementonPatientInvolvement.pdftInvolvement.pdf"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/S0277-9536(01)00135-6","volume":"54","author":"C Frankish","year":"2002","unstructured":"Frankish C, Kwan B, Ratner P, Wharf-Higgins J, Larsen C. Challenges of citizen participation in regional health authorities. Soc Sci Med. 2002;54:1471\u201380.","journal-title":"Soc Sci Med."},{"issue":"9220","key":"10_CR11","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/S0140-6736(00)02351-5","volume":"355","author":"D Tallon","year":"2000","unstructured":"Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037\u201340.","journal-title":"Lancet."},{"key":"10_CR12","volume-title":"Designing citizen-centered governance","author":"M Barnes","year":"2008","unstructured":"Barnes M, Skelcher C, Beirens H, Dalziel R, Jeffares S, Wilson L. Designing citizen-centered governance. Birmingham: Joseph Rowntree Foundation; 2008."},{"key":"10_CR13","doi-asserted-by":"crossref","unstructured":"Van De Bovenkamp HM, Trappenburg MJ, Grit KJ. Patient participation in collective healthcare decision making: the Dutch model. Heal Expect [Internet]. 2010 Feb 17;13(1):73\u201385. Available from: http:\/\/doi.wiley.com\/10.1111\/j.1369-7625.2009.00567.x","DOI":"10.1111\/j.1369-7625.2009.00567.x"},{"key":"10_CR14","doi-asserted-by":"crossref","unstructured":"Tritter JQ, McCallum, A. The snakes and ladders of user involvement: Moving beyond Arnstein. Health Policy (New York) [Internet]. 2006 Apr;76(2):156\u201368. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851005001314","DOI":"10.1016\/j.healthpol.2005.05.008"},{"key":"10_CR15","volume-title":"Voices off: tackling the democratic deficit in health","author":"L Cooper","year":"1995","unstructured":"Cooper L, Coote A, Davies A, Jackson C. Voices off: tackling the democratic deficit in health. London: Institute for Public Policy Research; 1995."},{"key":"10_CR16","unstructured":"Terzi A. The patients\u2019 involvement in health policies in Europe. [Internet]. Roma: Active Citizenship Network; 2013. Available from: http:\/\/www.activecitizenship.net\/files\/patients_rights\/7th_EPRD\/Patientsrights_acn_report_2013.pdf"},{"key":"10_CR17","doi-asserted-by":"publisher","DOI":"10.1787\/9789264195561-en","volume-title":"Citizens as Partners [Internet]","author":"OECD","year":"2001","unstructured":"OECD. Citizens as Partners [Internet]. Paris: OECD Publishing; 2001. Available from: http:\/\/www.oecd-ilibrary.org\/governance\/citizens-as-partners_9789264195561-en"},{"key":"10_CR18","unstructured":"European Commission. White Paper. Together for Health: A Strategic Approach for the EU 2008\u20132013 [Internet]. Brussels; 2007. Available from: http:\/\/ec.europa.eu\/health\/ph_overview\/Documents\/strategy_wp_en.pdf"},{"key":"10_CR19","doi-asserted-by":"crossref","unstructured":"Montgomery AA, Fahey, T. How do patients\u2019 treatment preferences compare with those of clinicians? Qual Saf Heal Care [Internet]. 2001 Sep 1;10(Supplement 1):i39\u201343. Available from: http:\/\/qualitysafety.bmj.com\/lookup\/doi\/10.1136\/qhc.0100039","DOI":"10.1136\/qhc.0100039"},{"key":"10_CR20","unstructured":"Sewitch MJ, Abrahamowicz M, Dobkin PL, Tamblyn R. Measuring differences between patients\u2019 and physicians\u2019 health perceptions: the patient-physician discordance scale. J Behav Med [Internet]. 2003 Jun;26(3):245\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12845937"},{"key":"10_CR21","doi-asserted-by":"crossref","unstructured":"Harrison JD. Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer. Arch Surg [Internet]. 2008 Apr 1;143(4):389. Available from: http:\/\/archsurg.jamanetwork.com\/article.aspx?doi=10.1001\/archsurg.143.4.389","DOI":"10.1001\/archsurg.143.4.389"},{"key":"10_CR22","unstructured":"da Silva JAP, Ramiro S, Pedro S, Rodrigues A, Vasconcelos JC, Benito-Garcia E. Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatol Port [Internet]. 2010;35(2):192\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20734542"},{"key":"10_CR23","doi-asserted-by":"crossref","unstructured":"Miravitlles M, Ferrer J, Bar\u00f3 E, Lleonart M, Galera J. Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med [Internet]. 2013 Dec;107(12):1977\u201385. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461111300231X","DOI":"10.1016\/j.rmed.2013.06.019"},{"key":"10_CR24","doi-asserted-by":"crossref","unstructured":"Fergusson D, Monfaredi Z, Pussegoda K, Garritty C, Lyddiatt A, Shea B, et al. The prevalence of patient engagement in published trials: a systematic review. Res Involv Engagem [Internet]. 2018 Dec 22;4(1):17. Available from: http:\/\/researchinvolvement.biomedcentral.com\/articles\/10.1186\/s40900-018-0099-x","DOI":"10.1186\/s40900-018-0099-x"},{"key":"10_CR25","doi-asserted-by":"crossref","unstructured":"Sacristan JA, Aguaron A, Avenda\u00f1o C, Garrido P, Carrion J, Gutierrez A, et al. Patient involvement in clinical research: why, when, and how. Patient Prefer Adherence [Internet]. 2016 Apr;631. Available from: www.dovepress.com\/patient-involvement-in-clinical-research-why-when-and-how-peer-reviewed-article-PPA","DOI":"10.2147\/PPA.S104259"},{"key":"10_CR26","doi-asserted-by":"crossref","unstructured":"Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving Patient Involvement in Medicines Research and Development: Ther Innov Regul Sci [Internet]. 2017 Sep 8;51(5):612\u20139. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/2168479017706405","DOI":"10.1177\/2168479017706405"},{"key":"10_CR27","doi-asserted-by":"crossref","unstructured":"Cook NS, Cave J, Holtorf A-P. Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs. Front Med [Internet]. 2019 Apr 24;6. Available from: www.frontiersin.org\/article\/10.3389\/fmed.2019.00082\/full","DOI":"10.3389\/fmed.2019.00082"},{"key":"10_CR28","unstructured":"Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC [Internet]. 2014. Available from: http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/reg_2014_536\/reg_2014_536_en.pdf"},{"key":"10_CR29","unstructured":"AVAC. Fact Sheet: Data Safety Monitoring Boards (DSMBs) [Internet]. 2011. Available from: www.avac.org\/sites\/default\/files\/resource-files\/DataSafetyMonitoringBoards2011.pdf"},{"key":"10_CR30","doi-asserted-by":"crossref","unstructured":"Huang GD, Bull J, Johnston McKee K, Mahon E, Harper B, Roberts JN. Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemp Clin Trials [Internet]. 2018 Mar;66:74\u20139. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171441730753X","DOI":"10.1016\/j.cct.2018.01.003"},{"key":"10_CR31","unstructured":"Summaries of Clinical Trial Results for Laypersons. Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536\/2014 on clinical trials on medicinal products for human use. Version 2 [Internet]. 2018. Available from: http:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/2017_01_26_summaries_of_ct_results_for_laypersons.pdf"},{"key":"10_CR32","doi-asserted-by":"crossref","unstructured":"Garfield S, Jheeta S, Husson F, Lloyd J, Taylor A, Boucher C, et al. The Role of Hospital Inpatients in Supporting Medication Safety: A Qualitative Study. Li D, editor. PLoS One [Internet]. 2016 Apr 19;11(4):e0153721. Available from: http:\/\/dx.plos.org\/10.1371\/journal.pone.0153721","DOI":"10.1371\/journal.pone.0153721"},{"key":"10_CR33","doi-asserted-by":"crossref","unstructured":"Oliver S. Patient involvement in setting research agendas. Eur J Gastroenterol Hepatol [Internet]. 2006 Sep;18(9):935\u20138. Available from: http:\/\/insights.ovid.com\/crossref?an=00042737-200609000-00001","DOI":"10.1097\/01.meg.0000230089.68545.45"},{"key":"10_CR34","doi-asserted-by":"crossref","unstructured":"Mavris M, Le Cam Y. Involvement of Patient Organisations in Research and Development of Orphan Drugs for Rare Diseases in Europe. Mol Syndromol [Internet]. 2012; Available from: www.karger.com\/Article\/FullText\/342758","DOI":"10.1159\/000342758"},{"key":"10_CR35","unstructured":"PCORI. Engagement Rubric for Applicants [Internet]. 2016. Available from: www.pcori.org\/sites\/default\/files\/Engagement-Rubric.pdf"},{"key":"10_CR36","unstructured":"Canadian Institutes of Health Research. Strategy for Patient-Oriented Research - Patient Engagement Framework [Internet]. 2014. Available from: http:\/\/www.cihr-irsc.gc.ca\/e\/documents\/spor_framework-en.pdf"},{"key":"10_CR37","unstructured":"NIHR | INVOLVE. Guidance on co-producing a research project [Internet]. 2018. Available from: www.invo.org.uk\/wp-content\/uploads\/2019\/04\/Copro_Guidance_Feb19front.jpg"},{"key":"10_CR38","doi-asserted-by":"crossref","unstructured":"Warner K, See W, Haerry D, Klingmann I, Hunter A, May M. EUPATI Guidance for Patient Involvement in Medicines Research and Development (R&D); Guidance for Pharmaceutical Industry-Led Medicines R&D. Front Med [Internet]. 2018 Oct 9;5. Available from: www.frontiersin.org\/article\/10.3389\/fmed.2018.00270\/full","DOI":"10.3389\/fmed.2018.00270"},{"key":"10_CR39","doi-asserted-by":"crossref","unstructured":"Klingmann I, Heckenberg A, Warner K, Haerry D, Hunter A, May M, et al. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Ethical Review of Clinical Trials. Front Med [Internet]. 2018 Sep 7;5. Available from: www.frontiersin.org\/article\/10.3389\/fmed.2018.00251\/full","DOI":"10.3389\/fmed.2018.00251"},{"key":"10_CR40","doi-asserted-by":"crossref","unstructured":"Ganz PA. Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life. JNCI Monogr [Internet]. 2001 Dec 1;2001(30):130\u20134. Available from: http:\/\/academic.oup.com\/jncimono\/article-lookup\/doi\/10.1093\/oxfordjournals.jncimonographs.a003450","DOI":"10.1093\/oxfordjournals.jncimonographs.a003450"},{"key":"10_CR41","doi-asserted-by":"crossref","unstructured":"Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet [Internet]. 2016 Feb;387(10021):857\u201365. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615011691","DOI":"10.1016\/S0140-6736(15)01169-1"},{"key":"10_CR42","doi-asserted-by":"crossref","unstructured":"Kluetz PG, Slagle A, Papadopoulos EJ, Johnson LL, Donoghue M, Kwitkowski VE, et al. Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms. Clin Cancer Res [Internet]. 2016 Apr 1;22(7):1553\u20138. Available from: http:\/\/clincancerres.aacrjournals.org\/cgi\/doi\/10.1158\/1078-0432.CCR-15-2035","DOI":"10.1158\/1078-0432.CCR-15-2035"},{"key":"10_CR43","doi-asserted-by":"crossref","unstructured":"Milman N, McConville E, Robson JC, Boonen A, Tugwell P, Wells GA, et al. Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. J Rheumatol [Internet]. 2019 Feb 1;jrheum.181073. Available from: http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.181073","DOI":"10.3899\/jrheum.181073"},{"key":"10_CR44","doi-asserted-by":"crossref","unstructured":"Richards T, Snow R, Schroter S. Logging The BMJ\u2019s \u201cpatient journey.\u201d BMJ [Internet]. 2015 Aug 17;h4396. Available from: www.bmj.com\/lookup\/doi\/10.1136\/bmj.h4396","DOI":"10.1136\/bmj.h4396"},{"key":"10_CR45","unstructured":"PCORI. Research Funding [Internet]. 2019. Available from: www.pcori.org\/sites\/default\/files\/PCORI-Research-Funding.pdf"},{"key":"10_CR46","unstructured":"National Institute for Health Research. Funding opportunities for research and career development [Internet]. 2017. Available from: www.nihr.ac.uk\/funding-and-support\/documents\/NIHRFundingOpportunitiesBooklet2017.pdf"},{"key":"10_CR47","unstructured":"European Commission. Horizon 2020. Public Engagement in Responsible Research and Innovation [Internet]. Available from: http:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/h2020-section\/public-engagement-responsible-research-and-innovation"},{"key":"10_CR48","unstructured":"Food and Drug Administration. Learn About FDA Patient Engagement [Internet]. Available from: www.fda.gov\/patients\/learn-about-fda-patient-engagement"},{"key":"10_CR49","unstructured":"European Medicines Agency. Patients and consumers [Internet]. Available from: www.ema.europa.eu\/en\/partners-networks\/patients-consumers"},{"key":"10_CR50","doi-asserted-by":"crossref","unstructured":"Haerry D, Landgraf C, Warner K, Hunter A, Klingmann I, May M, et al. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Regulatory Processes. Front Med [Internet]. 2018 Aug 17;5. Available from: www.frontiersin.org\/article\/10.3389\/fmed.2018.00230\/full","DOI":"10.3389\/fmed.2018.00230"},{"key":"10_CR51","doi-asserted-by":"crossref","unstructured":"Knox S. Health economic decision making in Europe\u00a0\u2013 a new priority for breast cancer advocacy. The Breast [Internet]. 2009 Apr;18(2):71\u20132. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977609000356","DOI":"10.1016\/j.breast.2009.03.002"},{"key":"10_CR52","doi-asserted-by":"crossref","unstructured":"Boutin M, Dewulf L, Hoos A, Geissler J, Todaro V, Schneider RF, et al. Culture and Process Change as a Priority for Patient Engagement in Medicines Development. Ther Innov Regul Sci [Internet]. 2017 Jan 20;51(1):29\u201338. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/2168479016659104","DOI":"10.1177\/2168479016659104"},{"key":"10_CR53","doi-asserted-by":"crossref","unstructured":"Scott AM, Wale JL. Patient advocate perspectives on involvement in HTA: an international snapshot. Res Involv Engagem [Internet]. 2017 Dec 10;3(1):2. Available from: http:\/\/researchinvolvement.biomedcentral.com\/articles\/10.1186\/s40900-016-0052-9","DOI":"10.1186\/s40900-016-0052-9"},{"key":"10_CR54","doi-asserted-by":"crossref","unstructured":"Hunter A, Facey K, Thomas V, Haerry D, Warner K, Klingmann I, et al. EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment. Front Med [Internet]. 2018 Sep 6;5. Available from: www.frontiersin.org\/article\/10.3389\/fmed.2018.00231\/full","DOI":"10.3389\/fmed.2018.00231"},{"key":"10_CR55","unstructured":"National Institute for Health and Care Excellence. Patient and public involvement policy [Internet]. [cited 2019 Jul 22]. Available from: www.nice.org.uk\/about\/nice-communities\/nice-and-the-public\/public-involvement\/public-involvement-programme\/patient-public-involvement-policy"},{"key":"10_CR56","unstructured":"IQWiG. Contributing the patients\u2019 perspective [Internet]. Available from: https:\/\/www.iqwig.de\/en\/participation\/contributing-the-patients-perspective.3070.html"},{"key":"10_CR57","doi-asserted-by":"crossref","unstructured":"Cris\u00f3stomo S, Santos M. Participa\u00e7\u00e3o p\u00fablica na sa\u00fade: das ideias \u00e0 a\u00e7\u00e3o em Portugal. Rev Crit Cienc Sociais [Internet]. 2018 Dec 1;(117):167\u201386. Available from: http:\/\/journals.openedition.org\/rccs\/8325","DOI":"10.4000\/rccs.8325"},{"key":"10_CR58","unstructured":"INFARMED. Doentes e associa\u00e7\u00f5es de doentes: Incluir [Internet]. [cited 2019 Jul 22]. Available from: http:\/\/www.infarmed.pt\/web\/infarmed\/cidadaos\/doentes-e-associacoes-de-doentes"},{"key":"10_CR59","unstructured":"Advisory Committee of the People with AIDS. The Denver Principles [Internet]. 1983. p. Available from: www.actupny.org\/documents\/Denver.html"},{"key":"10_CR60","doi-asserted-by":"crossref","unstructured":"Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. N Engl J Med [Internet]. 1987 Jul 23;317(4):185\u201391. Available from: http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJM198707233170401","DOI":"10.1056\/NEJM198707233170401"},{"key":"10_CR61","unstructured":"Crimp D. Before Occupy: How AIDS Activists Seized Control of the FDA in 1988. The Atlantic [Internet]. 2011 Dec 6; Available from: www.theatlantic.com\/health\/archive\/2011\/12\/before-occupy-how-aids-activists-seized-control-of-the-fda-in-1988\/249302"},{"key":"10_CR62","unstructured":"Lessem E. Nothing About Us Without Us: Community Engagement in Research to End the Epidemics. TAGline [Internet]. 2019;26(1). Available from: www.treatmentactiongroup.org\/sites\/default\/files\/tagline_may_2019_lessem_intro.pdf"},{"key":"10_CR63","doi-asserted-by":"crossref","unstructured":"Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet [Internet]. 2019 Mar;393(10178):1319\u201329. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618322773","DOI":"10.1016\/S0140-6736(18)32277-3"},{"key":"10_CR64","volume-title":"Global Hepatitis Report 2017 [Internet]","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global Hepatitis Report 2017 [Internet]. Geneva: World Health Organization; 2017. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf?sequence=1"},{"key":"10_CR65","doi-asserted-by":"crossref","unstructured":"Lomas J, Claxton K, Martin S, Soares M. Resolving the \u201cCost-Effective but Unaffordable\u201d Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value Heal [Internet]. 2018 Mar;21(3):266\u201375. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301517336136","DOI":"10.1016\/j.jval.2017.10.006"},{"key":"10_CR66","unstructured":"Millman AJ, Ntiri-Reid B, Irvin R, Kaufmann MH, Aronsohn A, Duchin JS, et al. Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series. Top Antivir Med [Internet]. 2017;25(3):110\u20133. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28820726"},{"key":"10_CR67","doi-asserted-by":"crossref","unstructured":"Douglass CH, Pedrana A, Lazarus J V., \u2018t Hoen EFM, Hammad R, Leite RB, et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med [Internet]. 2018 Dec 9;16(1):175. Available from: http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1162-z","DOI":"10.1186\/s12916-018-1162-z"},{"key":"10_CR68","doi-asserted-by":"crossref","unstructured":"Kieslich K, Ahn J, Badano G, Chalkidou K, Cubillos L, Hauegen RC, et al. Public participation in decision-making on the coverage of new antivirals for hepatitis C. Kieslich, Peter Littlejohns and Alb K, editor. J Health Organ Manag [Internet]. 2016 Aug 15;30(5):769\u201385. Available from: http:\/\/www.emeraldinsight.com\/doi\/10.1108\/JHOM-03-2016-0035","DOI":"10.1108\/JHOM-03-2016-0035"},{"key":"10_CR69","unstructured":"Kaplan K. Activist Satregies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries [Internet]. TAG\u00a0\u2013 Treatment Action Group; 2015. Available from: http:\/\/www.treatmentactiongroup.org\/sites\/default\/files\/201502\/ActivistStrategiesforHCVTx.pdf"},{"key":"10_CR70","doi-asserted-by":"crossref","unstructured":"Grillon C, Krishtel PR, Mellouk O, Basenko A, Freeman J, Mend\u00e3o L, et al. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind. J Int AIDS Soc [Internet]. 2018 Apr;21:e25060. Available from: http:\/\/doi.wiley.com\/10.1002\/jia2.25060","DOI":"10.1002\/jia2.25060"},{"key":"10_CR71","doi-asserted-by":"crossref","unstructured":"Chapman AR, Buckley T. Lowering the High Cost of Hepatitis C Drugs. J Pharm Care Heal Syst [Internet]. 2017;04(05). Available from: www.omicsonline.org\/open-access\/lowering-the-high-cost-of-hepatitis-c-drugs-2376-0419-1000187-95305.html","DOI":"10.4172\/2376-0419.1000187"},{"key":"10_CR72","doi-asserted-by":"crossref","unstructured":"Pii KH, Schou LH, Piil K, Jarden M. Current trends in patient and public involvement in cancer research: A systematic review. Heal Expect [Internet]. 2019 Feb;22(1):3\u201320. Available from: http:\/\/doi.wiley.com\/10.1111\/hex.12841","DOI":"10.1111\/hex.12841"},{"key":"10_CR73","doi-asserted-by":"crossref","unstructured":"Vaz-Luis I, O\u2019Neill A, Sepucha K, Miller KD, Baker E, Dang CT, et al. Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer [Internet]. 2017 Aug 1;123(15):2821\u20138. Available from: http:\/\/doi.wiley.com\/10.1002\/cncr.30671","DOI":"10.1002\/cncr.30671"},{"issue":"3","key":"10_CR74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1684\/ejd.2016.2747","volume":"26","author":"E Dika","year":"2016","unstructured":"Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatology. 2016;26(3):232\u20139.","journal-title":"Eur J Dermatology."},{"key":"10_CR75","doi-asserted-by":"crossref","unstructured":"Castellanos EH, Chen S, Drexler H, Horn L. Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents. J Natl Compr Canc Netw [Internet]. 2015 Dec;13(12):1490\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26656518","DOI":"10.6004\/jnccn.2015.0177"},{"key":"10_CR76","doi-asserted-by":"crossref","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies. J Am Acad Dermatol [Internet]. 2015 Feb;72(2):203\u201318. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962214017630","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"10_CR77","doi-asserted-by":"crossref","unstructured":"Trask PC, Dueck AC, Piault E, Campbell A. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials. Clin Trials [Internet]. 2018 Dec 19;15(6):616\u201323. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/1740774518799985","DOI":"10.1177\/1740774518799985"},{"key":"10_CR78","doi-asserted-by":"crossref","unstructured":"Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, et al. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Ann Oncol [Internet]. 2018 Dec 1;29(12):2288\u201395. Available from: https:\/\/academic.oup.com\/annonc\/article\/29\/12\/2288\/5126229","DOI":"10.1093\/annonc\/mdy449"},{"key":"10_CR79","doi-asserted-by":"crossref","unstructured":"Catt S, Starkings R, Shilling V, Fallowfield L. Patient-reported outcome measures of the impact of cancer on patients\u2019 everyday lives: a systematic review. J Cancer Surviv [Internet]. 2017 Apr 10;11(2):211\u201332. Available from: http:\/\/link.springer.com\/10.1007\/s11764-016-0580-1","DOI":"10.1007\/s11764-016-0580-1"},{"key":"10_CR80","doi-asserted-by":"crossref","unstructured":"Vitry A, Nguyen T, Entwistle V, Roughead E. Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. J Pharm Policy Pract [Internet]. 2015 Dec 19;8(1):25. Available from: http:\/\/www.joppp.org\/content\/8\/1\/25","DOI":"10.1186\/s40545-015-0046-2"},{"key":"10_CR81","doi-asserted-by":"crossref","unstructured":"Gabe J, Chamberlain K, Norris P, Dew K, Madden H, Hodgetts D. The debate about the funding of Herceptin: A case study of \u2018countervailing powers\u2019. Soc Sci Med [Internet]. 2012 Dec;75(12):2353\u201361. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0277953612006727","DOI":"10.1016\/j.socscimed.2012.09.009"},{"key":"10_CR82","unstructured":"European Cancer Patient Coalition. Europe of Disparities [Internet]. [cited 2019 Jul 26]. Available from: http:\/\/www.ecpc.org\/activities\/policy-and-advocacy\/policy-initiatives\/europe-of-disparities"},{"key":"10_CR83","unstructured":"Mcmillan Cancer Support. We make change happen [Internet]. [cited 2019 Jul 26]. Available from: www.macmillan.org.uk\/about-us\/what-we-do\/we-make-change-happen"},{"key":"10_CR84","unstructured":"Banks M. MEPs launch \u2018elections manifesto\u2019 in fight against cancer. The Parliament Magazine [Internet]. 2019 Jan 29; Available from: www.theparliamentmagazine.eu\/articles\/news\/meps-launch-\u2018elections-manifesto\u2019-fight-against-cancer"},{"key":"10_CR85","unstructured":"The All Party Parliamentary Group on Cancer. Report of the All Party Parliamentary Group on Cancer\u2019s Inquiry into Inequalities in Cancer [Internet]. 2009. Available from: https:\/\/www.macmillan.org.uk\/documents\/getinvolved\/campaigns\/appg\/britainagainstcancer2009\/cancerinequalitiesreport.pdf"},{"key":"10_CR86","doi-asserted-by":"crossref","unstructured":"Gordon A, Gordon L. The Progeria Research Foundation: its remarkable journey from obscurity to treatment. Expert Opin Orphan Drugs [Internet]. 2014 Nov 30;2(11):1187\u201395. Available from: http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/21678707.2014.970172","DOI":"10.1517\/21678707.2014.970172"},{"key":"10_CR87","unstructured":"ALS Association. ALS Ice Bucket Challenge Commitments [Internet]. [cited 2019 Jul 22]. Available from: http:\/\/www.alsa.org\/fight-als\/ice-bucket-challenge-spending.html"},{"key":"10_CR88","unstructured":"AKU Society. DevelopAKUre [Internet]. [cited 2019 Jul 22]. Available from: www.developakure.eu"},{"key":"10_CR89","unstructured":"Parent Project Muscular Dystrophy. Research [Internet]. [cited 2019 Jul 22]. Available from: www.parentprojectmd.org\/research"},{"key":"10_CR90","unstructured":"Findacure. Drug repurposing [Internet]. [cited 2019 Jul 22]. Available from: www.findacure.org.uk\/drug-repurposing"},{"key":"10_CR91","unstructured":"NORD. Programs and Services [Internet]. [cited 2019 Jul 22]. Available from: http:\/\/rarediseases.org\/about\/what-we-do\/programs-services"}],"container-title":["Global Pharmaceutical Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-15-2724-1_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T07:33:56Z","timestamp":1647934436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-15-2724-1_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9789811527234","9789811527241"],"references-count":91,"URL":"https:\/\/doi.org\/10.1007\/978-981-15-2724-1_10","relation":{},"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"16 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}